BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.
LSI Europe Summit
September 28 – October 2, 2026 | Grand Hyatt Barcelona, Spain
Register interest: info@betaglue.com
CIRSE Annual Congress
September 5-9, 2026 | Copenhagen,
Denmark
Register interest: info@betaglue.com
European Society for Medical Oncology
July 1-4, 2026 | ICM, Munich,
Germany
Register interest: info@betaglue.com
American Society of Clinical Oncology
May 29-June 2, 2026 | McCormick Place, Chicago (IL) – USA & Online
Register interest: info@betaglue.com
Annual Scientific Meeting
11-15 April, 2026 | Metro Toronto Convention Centre – Toronto (ON), Canada
Register interest: info@betaglue.com
LSI USA Summit
March 16-20, 2026 | Monarch Beach, Dana Point,
(CA) – USA
Register interest: info@betaglue.com
World Congress of Interventional Oncology
January 26-27, 2026 | Rome
Register interest: info@betaglue.com
Advancements in the fight against cancer
January 15-17, 2026 | Miami (FL), USA
Register interest: info@betaglue.com
44th Annual J.P. Morgan
January 12-15, 2026 | San Francisco, California
Register interest: info@betaglue.com
Milan, August 14th 2026 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…
Read moreBetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the…
Read moreMilan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced…
Read more
